NTLAIntellia Therapeutics, Inc.

1. Sep 8, 2026Also on September 8, 2026, the Company announced that the U.S. Food and Drug Administration (“FDA”) has accepted the Biologics License Application (“BLA”) for lonvoguran ziclumeran (“lonvo-z”) and granted the BLA Priority Review with a Prescription Drug User Fee Act (“PDUFA”) target action date of March 10, 2027.Regulation FD disclosure · Form 8-K
2. Sep 4, 2026On September 4, 2026 (the “Closing Date”), Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into a Credit Agreement (the “Credit Agreement”) with the lenders from time to time party thereto (“Lenders”), and OrbiMed Royalty & Credit Opportunities V, LP, as administrative agent (“Administrative Agent”)Material agreement entered · Form 8-K
3. Aug 6, 2026Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates.Earnings release · press release
4. Jun 15, 2026On June 13, 2026, the Company announced additional positive results from the global Phase 3 HAELO clinical trial of lonvoguran ziclumeran or “lonvo-z” (formerly NTLA-2002) for hereditary angioedema (“HAE”)Regulation FD disclosure · Form 8-K
5. May 11, 2026Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates.Earnings release · press release
6. Apr 30, 2026On April 28, 2026, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. (the “Underwriters”), related to a public offering (the “Offering”) of 16,744,187 shares of …Material agreement entered · Form 8-K
7. Apr 27, 2026Updates about Lonvo-z for the Treatment of HAE On April 27, 2026, Intellia announced positive topline results from the global Phase 3 HAELO clinical trial of lonvo-z in HAE. Lonvo-z is an in vivo CRISPR gene editing candidate that is designed as a one-time treatment, administered in an outpatient setting, to …Regulation FD disclosure · Form 8-K
8. Apr 10, 2026On April 7, 2026, based on the recommendation of the nominating and corporate governance committee of the board of directors (the “Board”) of Intellia Therapeutics, Inc. (the “Company”), the Board adopted amendments to the Company’s Third Amended and Restated By-laws.Charter/bylaw amendment or fiscal-year change · Form 8-K
9. Mar 2, 2026Intellia Therapeutics, Inc. (the “Company”) previously entered into an Open Market Sale Agreement, dated March 4, 2022, and amended on February 23, 2024 (as amended, the “Sales Agreement”) with Jefferies LLC (“Jefferies”) with respect to an at-the-market offering program under which the Company may offer and sell …Material agreement entered · Form 8-K
10. Feb 26, 2026Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025.Earnings release · press release
11. Jan 27, 2026On January 27, 2026, Intellia announced that the U.S. Food and Drug Administration (“FDA”) has removed the clinical hold on the investigational new drug application (“IND”) for the MAGNITUDE-2 Phase 3 clinical trial of nexiguran ziclumeran (“nex-z”) for patients with hereditary transthyretin (“ATTR”) amyloidosis with …Regulation FD disclosure · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.